

Two UK commercial evaluations closing successfully

Q-linea AB (publ) (OMX: QLINEA) today announces that Pro-lab Diagnostics, its exclusive distribution partner for the UK, has closed another two commercial evaluations.

The two large hospitals are both reviewing their workstreams for the treatment of patients with bloodstream infections and decided to explore rapid AST from positive blood culture to improve clinical care. A combined total of 154 patients and contrived samples were investigated and compared with the current standard of care. Results showed very good overall concordance with a significant reduction in time to optimal therapy. Results are expected to be published.

Mark Reed, General Manager at Pro-Lab Diagnostics commented:" We are very pleased to see another strong outcome in clinical evaluations and proceed with both sites into commercial discussions on how to implement ASTar into their clinical routine. There is a growing interest amongst our customers in the UK to investigate these novel technologies fueled by the increasing rates of antimicrobial resistance and political initiatives to counteract this emerging threat."

For more information, please contact:

Stuart Gander, President & CEO, Q-linea Stuart.Gander@qlinea.com +1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB Christer.Samuelsson@qlinea.com +46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

Two UK commercial evaluations closing successfully